🧩
Free audit · No signup
Tool Sprawl Risk Audit — Biotech
Find out how much spreadsheet and SaaS sprawl is costing Biotech — and where a purpose-built internal tool pays off.
Signs of tool sprawl in Biotech
- R&D timelines are 10-15 years and the cost per approved drug is in the billions — every operating decision is filtered through 'how does this affect time-to-IND, time-to-readout, time-to-NDA'.
- FDA and EMA regulatory readiness is non-negotiable — the IND, the NDA, the BLA, and every clinical trial design has to survive regulator examination, and the documentation infrastructure has to be audit-ready continuously.
- Clinical trial operations are the largest single line of cost — site selection, patient recruitment, monitoring, data management, and trial conduct are operationally intense and the largest leverage on cycle time.
- AI-native drug discovery competitors have raised billions on the bet that ML on biological data structurally compresses early R&D — the incumbent biotech has to absorb the AI capability without disrupting the regulated infrastructure already built.
Section 1 of 4 · Source of Truth0/8 answered
Source of Truth
Whether your operational data lives in one place or is scattered across tools.
Ran the numbers? Let’s act on them.
Send us the result and the constraint behind it. We’ll scope the diagnostic, sprint, or build that fixes what the score reveals.